Latest Alkynes Stories
SHENZHEN, China, April 16, 2013 /PRNewswire/ -- Chipscreen Biosciences, a leading integrated Chinese biotech company specialized in discovery and development of novel small molecule pharmaceuticals with a primary focus in oncology, metabolic disease, and autoimmune diseases, today announced the achievement of the primary endpoint in the pivotal, registrational Phase 2 CHIPEL trial of Chidamide (Epidaza(®)), an orally active benzamide type of class I-selective histone deacetylase...
CAMBRIDGE, Mass., April 4, 2013 /PRNewswire-USNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) today announced that one cohort of a Phase 2 non-small cell lung cancer (NSCLC) study did not meet its primary endpoint. The cohort evaluated MM-121 in combination with erlotinib to treat patients with NSCLC whose disease progressed on an anti-EGFR tyrosine kinase inhibitor (EGFR-TKI). MM-121 is being evaluated in two additional NSCLC cohorts as well as Phase 2 studies for the...
SAN DIEGO, March 14, 2013 /PRNewswire-USNewswire/ -- Three studies released today present possible positive news for people with Parkinson's disease. The studies, which will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013, report on treatments for blood pressure problems, the wearing-off that can occur when people have taken the main drug for Parkinson's for a long time, and for people early in the disease whose symptoms are...
LONDON, February 22, 2013 /PRNewswire/ -- Biotech sector has a promising future. With the rise in occupational and lifestyle ailments, the demand for biotech products is expected to rise. Increased age expectancy is another major factor behind the growth of the sector. However, biotech companies work in an uncertain environment and the fortunes of a company may make or break with a single FDA decision. Ariad Pharmaceuticals Inc. (NASDAQ: ARIA) recently received approval for...
CRESSKILL, N.J., Jan. 11, 2013 /PRNewswire/ -- The trial date for over 1,000 NuvaRing lawsuits is being extended, feeding rumors that the vaginal ring contraceptive's manufacturer, Merck, may be ready to enter settlement negotiations. The lawsuits allege that NuvaRing caused serious side effects, including blood clots, deep vein thrombosis, pulmonary embolism, heart attacks, strokes, and wrongful death. The multidistrict litigation before Rodney W. Sippel of the U.S. District Court,...
WAYNE, N.J., Jan. 10, 2013 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Skyla((TM)) (levonorgestrel-releasing intrauterine system) 13.5 mg, a new hormone-releasing system that is placed in the uterus for the prevention of pregnancy for up to three years.[1] "Research shows that nearly 50 percent of pregnancies in the U.S. are unintended,(2) which emphasizes the need for increased education and...
WAYNE, N.J., Jan. 9, 2013 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Skyla((TM)) (levonorgestrel-releasing intrauterine system) 13.5 mg, a new hormone-releasing system that is placed in the uterus for the prevention of pregnancy for up to three years.[1] (Photo: http://photos.prnewswire.com/prnh/20130109/MM19804-a) (Photo: http://photos.prnewswire.com/prnh/20130109/MM19804-b) "Research shows...
Women with polycystic ovary syndrome (PCOS) who are taking combined oral contraceptives have a 2-fold risk of blood clots compared with women without the disorder who take contraceptives, states a study published in CMAJ (Canadian Medical Association Journal). PCOS affects between 6% and 10% of women of reproductive age with some estimates as high as 15%, making it the most common endocrine disorder in this age group. Risk factors for heart disease such as hypertension, diabetes, obesity...
ST. PAUL, Minn., Nov. 30, 2012 /PRNewswire/ -- Nearly a quarter of patients taking erlotinib (Tarceva®) for treatment of advanced non-small cell lung cancer (NSCLC) did not receive the recommended pharmacogenomic (PGx) testing prior to the start of treatment, according to a new study by pharmacy benefit manager Prime Therapeutics (Prime), in collaboration with Jonas de Souza, MD, Instructor of Medicine, Section of Hematology/Oncology, University of Chicago Medical Center. The study...
NORTHBROOK, Ill., Nov. 20, 2012 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), today announced it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for Tarceva(®) (erlotinib) tablets for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor...
